MX2023000784A - Anticuerpos contra el dominio extracelular de muc1-c (muc1-c/ecd). - Google Patents
Anticuerpos contra el dominio extracelular de muc1-c (muc1-c/ecd).Info
- Publication number
- MX2023000784A MX2023000784A MX2023000784A MX2023000784A MX2023000784A MX 2023000784 A MX2023000784 A MX 2023000784A MX 2023000784 A MX2023000784 A MX 2023000784A MX 2023000784 A MX2023000784 A MX 2023000784A MX 2023000784 A MX2023000784 A MX 2023000784A
- Authority
- MX
- Mexico
- Prior art keywords
- muc1
- ecd
- extracellular domain
- antibodies against
- antibodies
- Prior art date
Links
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 abstract 1
- 102100034256 Mucin-1 Human genes 0.000 abstract 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063052599P | 2020-07-16 | 2020-07-16 | |
| PCT/US2021/070881 WO2022016190A1 (en) | 2020-07-16 | 2021-07-15 | Antibodies against the muc1-c/extracellular domain (muc1-c/ecd) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000784A true MX2023000784A (es) | 2023-04-18 |
Family
ID=79554266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000784A MX2023000784A (es) | 2020-07-16 | 2021-07-15 | Anticuerpos contra el dominio extracelular de muc1-c (muc1-c/ecd). |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230265208A1 (enExample) |
| EP (1) | EP4182354A4 (enExample) |
| JP (1) | JP2023534959A (enExample) |
| KR (1) | KR20230116767A (enExample) |
| CN (1) | CN117693530A (enExample) |
| AU (1) | AU2021310499A1 (enExample) |
| BR (1) | BR112023000728A2 (enExample) |
| CA (1) | CA3186181A1 (enExample) |
| IL (1) | IL299903A (enExample) |
| MX (1) | MX2023000784A (enExample) |
| WO (1) | WO2022016190A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202436357A (zh) * | 2023-03-03 | 2024-09-16 | 瑞士商百濟神州瑞士有限責任公司 | Ｍｕｃ１抗體及使用方法 |
| TW202436343A (zh) * | 2023-03-03 | 2024-09-16 | 瑞士商百濟神州瑞士有限責任公司 | Muc1與cd16a抗體以及其使用方法 |
| WO2025217515A2 (en) | 2024-04-12 | 2025-10-16 | Dana-Farber Cancer Institute, Inc. | Identification of muc1-c as a target for the treatment of squamous cell carcinomas |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2601417C (en) * | 2004-07-01 | 2018-10-30 | Novo Nordisk A/S | Human anti-kir antibodies |
| EP3130607B1 (en) * | 2008-10-06 | 2024-04-17 | Minerva Biotechnologies Corporation | Muc1* antibodies |
| CN106132992B (zh) * | 2014-01-29 | 2020-08-07 | 达娜-法勃肿瘤研究所公司 | 针对muc1-c/胞外结构域(muc1-c/ecd)的抗体 |
| US10617773B2 (en) * | 2016-08-05 | 2020-04-14 | Dana-Farber Cancer Institute, Inc. | Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD) |
-
2021
- 2021-07-15 US US18/005,562 patent/US20230265208A1/en active Pending
- 2021-07-15 AU AU2021310499A patent/AU2021310499A1/en active Pending
- 2021-07-15 BR BR112023000728A patent/BR112023000728A2/pt unknown
- 2021-07-15 WO PCT/US2021/070881 patent/WO2022016190A1/en not_active Ceased
- 2021-07-15 CA CA3186181A patent/CA3186181A1/en active Pending
- 2021-07-15 EP EP21842547.8A patent/EP4182354A4/en active Pending
- 2021-07-15 JP JP2023502897A patent/JP2023534959A/ja active Pending
- 2021-07-15 IL IL299903A patent/IL299903A/en unknown
- 2021-07-15 KR KR1020237005383A patent/KR20230116767A/ko active Pending
- 2021-07-15 MX MX2023000784A patent/MX2023000784A/es unknown
- 2021-07-15 CN CN202180063154.3A patent/CN117693530A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117693530A (zh) | 2024-03-12 |
| EP4182354A4 (en) | 2024-12-25 |
| KR20230116767A (ko) | 2023-08-04 |
| JP2023534959A (ja) | 2023-08-15 |
| BR112023000728A2 (pt) | 2023-03-21 |
| AU2021310499A1 (en) | 2023-03-09 |
| CA3186181A1 (en) | 2022-01-20 |
| IL299903A (en) | 2023-03-01 |
| EP4182354A1 (en) | 2023-05-24 |
| WO2022016190A1 (en) | 2022-01-20 |
| US20230265208A1 (en) | 2023-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023000784A (es) | Anticuerpos contra el dominio extracelular de muc1-c (muc1-c/ecd). | |
| AU2018449846A8 (en) | An anti-B7-H3 antibody | |
| TN2019000272A1 (en) | Anti-ilt4 antibodies and antigen-binding fragments. | |
| PH12019550153A1 (en) | Combination therapies for treatment of bcma-related cancers and autoimmune disorders | |
| MX2024009280A (es) | Anticuerpos anti proteina de muerte programada 1 (pd-1) y usos de estos. | |
| PH12020500671A1 (en) | Antibodies specific for gucy2c and uses thereof | |
| MX2021015888A (es) | Fusión de un anticuerpo que se une a cea y 4-1bbl. | |
| WO2019182867A8 (en) | Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor | |
| EP4442278A3 (en) | Humanized antibodies against c-kit | |
| WO2021067776A3 (en) | Anti-pd-l1 antibodies and antibody-drug conjugates | |
| EA202191785A1 (ru) | Антитела к ctla4 и способы их применения | |
| EA201890934A1 (ru) | Антитела против cd134 (ox40) и их применение | |
| MX2021015495A (es) | Composiciones y métodos para tratar cáncer. | |
| WO2022051591A3 (en) | Nectin-4 antibodies and uses thereof | |
| PH12020551968A1 (en) | Anti-sez6 antibody drug conjugates and methods of use | |
| MX2022014224A (es) | Construcciones de anticuerpos de dominio individual neutralizantes contra sars-cov2. | |
| CL2022002520A1 (es) | Anticuerpos anti-sea de muc1 | |
| EP4501355A3 (en) | Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor | |
| MX2020011614A (es) | Anticuerpos con perfiles de glicanos modulados. | |
| WO2021016062A8 (en) | Chimeric antigen receptors containing glypican 2 binding domains | |
| MX2024002182A (es) | Proteinas de union al factor de crecimiento transformante receptor beta ii (tgf-beta-rii). | |
| MX2023012300A (es) | Anticuerpos humanos contra artemina y metodos de uso de estos. | |
| BR112022012872A2 (pt) | Composição e uso de anticorpos monoclonais geneticamente modificados refratários a fatores imunossupressivos tumorais | |
| MX2023014109A (es) | Constructos de anticuerpos multiespecificos contra dominio extracelular/muc1-c (muc1-c/ecd). | |
| MX2021002077A (es) | Nuevas composiciones de anticuerpos para la inmunoterapia contra el cáncer. |